Six-Transmembrane Epithelial Antigen of Prostate 4: An Indicator of Prognosis and Tumor Immunity in Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67(1):103–117. doi:10.1146/annurev-med-090514-013832
   PubMed Web of Science ®Google Scholar
• Ahn JC, Lee YT, Agopian VG, et al. Hepatocellular carcinoma surveillance: current practice and future directions. Hepatoma Res. 2022;8:10. doi:10.20517/2394-5079.2021.131
   PubMedGoogle Scholar
• Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer. 2020;147:317–330.
   PubMed Web of Science ®Google Scholar
• Müller M, Bird TG, Nault JC. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J Hepatol. 2020;72:990–1002.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–545.
   PubMed Web of Science ®Google Scholar
• Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. 2021;22:5801.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–550.
   PubMed Web of Science ®Google Scholar
• Rocha SM, Barroca-Ferreira J, Passarinha LA, Socorro S, Maia CJ. The usefulness of STEAP proteins in prostate cancer clinical practice. In: Bott SRJ, Ng KL, editors. Prostate Cancer. Brisbane (AU): Exon Publications; 2021.
   Google Scholar
• Scarl RT, Lawrence CM, Gordon HM, Nunemaker CS. STEAP4: its emerging role in metabolism and homeostasis of cellular iron and copper. J Endocrinol. 2017;234:R123–R134. doi:10.1530/JOE-16-0594
   PubMed Web of Science ®Google Scholar
• Pihlstrøm N, Jin Y, Nenseth Z, Kuzu OF, Saatcioglu F. STAMP2 expression mediated by cytokines attenuates their growth-limiting effects in prostate cancer cells. Cancers. 2021;13:1579. doi:10.3390/cancers13071579
   PubMed Web of Science ®Google Scholar
• Burnell SEA, Spencer-Harty S, Howarth S, et al. Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer. PLoS One. 2019;14:e0220456. doi:10.1371/journal.pone.0220456
   PubMed Web of Science ®Google Scholar
• Xue X, Bredell BX, Anderson ER, et al. Quantitative proteomics identifies STEAP4 as a critical regulator of mitochondrial dysfunction linking inflammation and colon cancer. Proc Natl Acad Sci U S A. 2017;114(45):E9608–E9617. doi:10.1073/pnas.1712946114
   PubMed Web of Science ®Google Scholar
• Orfanou IM, Argyros O, Papapetropoulos A, Tseleni-Balafouta S, Vougas K, Tamvakopoulos C. Discovery and pharmacological evaluation of STEAP4 as a novel target for HER2 overexpressing breast cancer. Front Oncol. 2021;11:608201. doi:10.3389/fonc.2021.608201
   PubMed Web of Science ®Google Scholar
• Giannini EG, Farinati F, Ciccarese F, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61(1):184–190. doi:10.1002/hep.27443
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. doi:10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38:4317–4345. doi:10.1200/JCO.20.02672
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514. doi:10.1093/nar/gkaa407
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18–27. doi:10.1016/j.neo.2022.01.001
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Lánczky A, Győrffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res. 2021;23:e27633. doi:10.2196/27633
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30. doi:10.1093/nar/28.1.27
   PubMed Web of Science ®Google Scholar
• Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–W560. doi:10.1093/nar/gkz430
   PubMed Web of Science ®Google Scholar
• Li C, Tang Z, Zhang W, Ye Z, Liu F. GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA. Nucleic Acids Res. 2021;49(W1):W242–W246. doi:10.1093/nar/gkab418
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35:4200–4202. doi:10.1093/bioinformatics/btz210
   PubMed Web of Science ®Google Scholar
• Invernizzi G, Papaleo E, Sabate R, Ventura S. Protein aggregation: mechanisms and functional consequences. Int J Biochem Cell Biol. 2012;44:1541–1554. doi:10.1016/j.biocel.2012.05.023
   PubMed Web of Science ®Google Scholar
• Scheibel T, Buchner J. Protein aggregation as a cause for disease. Handb Exp Pharmacol. 2006;172:199–219.
   PubMedGoogle Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.
   PubMed Web of Science ®Google Scholar
• Julie G, Domitile C, Jean-frederic B, et al. Hepatocellular carcinoma immune landscape and the potential of immunotherapies. Front Immunol. 2021;12:655697.
   PubMedGoogle Scholar
• Li W, Yin X, Yan Y, Liu C, Li G. STEAP4 knockdown inhibits the proliferation of prostate cancer cells by activating the cGMP-PKG pathway under lipopolysaccharide-induced inflammatory microenvironment. Int Immunopharmacol. 2021;101(Pt B):108311.
   PubMedGoogle Scholar
• Chen H, Xu C, Yu Q, et al. Comprehensive landscape of STEAP family functions and prognostic prediction value in glioblastoma. J Cell Physiol. 2021;236:2988–3000.
   PubMed Web of Science ®Google Scholar
• Yoo SK, Cheong J, Kim HY. STAMPing into mitochondria. Int J Biol Sci. 2014;10:321–326.
   PubMed Web of Science ®Google Scholar
• Kim HY, Kwon WY, Park JB, et al. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease. FASEB J. 2020;34:12354–12366.
   PubMed Web of Science ®Google Scholar
• Kim HY, Cho HK, Yoo SK, Cheong JH. Hepatic STAMP2 decreases hepatitis B virus X protein-associated metabolic deregulation. Exp Mol Med. 2012;44:622–632.
   PubMed Web of Science ®Google Scholar
• Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: i have a DREAM. Cell Death Differ. 2018;25:114–132.
   PubMed Web of Science ®Google Scholar
• Krutsenko Y, Singhi AD, Monga SP. β-catenin activation in hepatocellular cancer: implications in biology and therapy. Cancers. 2021;13:1830.
   PubMed Web of Science ®Google Scholar
• Korkmaz CG, Korkmaz KS, Kurys P, et al. Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene. 2005;24:4934–4945.
   PubMed Web of Science ®Google Scholar
• Tang Y, Wang Y, Xu X, Sun H, Tang W. STEAP4 promoter methylation correlates with tumorigenesis of hepatocellular carcinoma. Pathol Res Pract. 2022;233:153870.
   PubMed Web of Science ®Google Scholar
• Xia Y, Brown ZJ, Huang H, Tsung A. Metabolic reprogramming of immune cells: shaping the tumor microenvironment in hepatocellular carcinoma. Cancer Med. 2021;10:6374–6383.
   PubMed Web of Science ®Google Scholar
• Chen R, Zhao M, An Y, Liu D, Tang Q, Teng G. A prognostic gene signature for hepatocellular carcinoma. Front Oncol. 2022;12:841530.
   PubMedGoogle Scholar
• Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell. 2019;179:561–577.
   PubMed Web of Science ®Google Scholar
• Giraldo NA, Sanchez-Salas R, Peske JD, et al. The clinical role of the TME in solid cancer. Br J Cancer. 2019;120(1):45–53.
   PubMed Web of Science ®Google Scholar
• Jiang P, Lee W, Li X, et al. Genome-scale signatures of gene interaction from compound screens predict clinical efficacy of targeted cancer therapies genome-scale signatures of gene interaction from compound screens predict clinical efficacy of targeted cancer therapies. Cell Syst. 2018;6:343–354.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.
   PubMed Web of Science ®Google Scholar
• Liu J, Ma Q, Zhang M, et al. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer. 2012;48(15):2328–2338.
   PubMed Web of Science ®Google Scholar
• Mo Z, Wang Y, Cao Z, et al. An integrative analysis reveals the underlying association between CTNNB1 mutation and immunotherapy in hepatocellular carcinoma. Front Oncol. 2020;10:853.
   PubMed Web of Science ®Google Scholar
• Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586–2593.
   PubMed Web of Science ®Google Scholar
• Tu JF, Ding YH, Ying XH, et al. Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. Sci Rep. 2016;6:35056.
   PubMed Web of Science ®Google Scholar
• Ding W, Tan Y, Qian Y, et al. Clinicopathologic and prognostic significance of tumor-associated macrophages in patients with hepatocellular carcinoma: a meta-analysis. PLoS One. 2019;14:e0223971.
   PubMed Web of Science ®Google Scholar
• Dong P, Ma L, Liu L, et al. CD86+/CD206+, Diametrically Polarized Tumor-Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis. Int J Mol Sci. 2016;17:320.
   PubMed Web of Science ®Google Scholar